WO2005074968A3 - Medical use of basic peptides - Google Patents

Medical use of basic peptides Download PDF

Info

Publication number
WO2005074968A3
WO2005074968A3 PCT/EP2005/001255 EP2005001255W WO2005074968A3 WO 2005074968 A3 WO2005074968 A3 WO 2005074968A3 EP 2005001255 W EP2005001255 W EP 2005001255W WO 2005074968 A3 WO2005074968 A3 WO 2005074968A3
Authority
WO
WIPO (PCT)
Prior art keywords
basic peptides
medical use
apoptosis
provides
peptides
Prior art date
Application number
PCT/EP2005/001255
Other languages
French (fr)
Other versions
WO2005074968A2 (en
Inventor
Bert Schutte
Franciscus C S Ramaekers
Original Assignee
Univ Maastricht
Bert Schutte
Franciscus C S Ramaekers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maastricht, Bert Schutte, Franciscus C S Ramaekers filed Critical Univ Maastricht
Publication of WO2005074968A2 publication Critical patent/WO2005074968A2/en
Publication of WO2005074968A3 publication Critical patent/WO2005074968A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4741—Keratin; Cytokeratin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to the field of apoptosis-related diseases. The invention provides for basic peptides as biologically active substances to modulate apoptosis when produced in or introduced into cells involved in apoptosis. The invention also provides for nucleic acids encoding the basic peptides.
PCT/EP2005/001255 2004-02-10 2005-02-08 Medical use of basic peptides WO2005074968A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04447036.7 2004-02-10
EP04447036 2004-02-10

Publications (2)

Publication Number Publication Date
WO2005074968A2 WO2005074968A2 (en) 2005-08-18
WO2005074968A3 true WO2005074968A3 (en) 2005-12-08

Family

ID=34833848

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/001255 WO2005074968A2 (en) 2004-02-10 2005-02-08 Medical use of basic peptides

Country Status (1)

Country Link
WO (1) WO2005074968A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019174610A1 (en) * 2018-03-14 2019-09-19 蔡立刚 Oncolytic virus and synthetic dna sequence, and application thereof

Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3639580A (en) * 1970-01-08 1972-02-01 Akio Nagata Antibiotic tuberactinomycin and process for preparing same
US3880994A (en) * 1972-12-06 1975-04-29 Bristol Myers Co Antibiotic BU-1880
JPS511692A (en) * 1974-06-26 1976-01-08 Asahi Chemical Ind KOSEIBUTSUSHITSUKORISUCHINNO SEISEIHO
US4091092A (en) * 1976-09-20 1978-05-23 E. R. Squibb & Sons, Inc. Polymyxin F and process of producing polymyxin F
JPS63264599A (en) * 1987-04-20 1988-11-01 Takeda Chem Ind Ltd Antibiotic substance tan-865 and production thereof
JPH03206099A (en) * 1989-12-29 1991-09-09 Kaken Pharmaceut Co Ltd Antibiotic ksy-5 and production thereof
JPH0532557A (en) * 1991-02-27 1993-02-09 Morinaga Milk Ind Co Ltd Agent for promoting production of nerve growth factor
WO1993011783A1 (en) * 1991-12-09 1993-06-24 Magainin Pharmaceuticals Inc. Composition and treatment with biologically active peptides and chelating agents
WO1993024150A1 (en) * 1992-05-28 1993-12-09 Zeneca Limited Salts of peptides with carboxy-terminated polyesters
WO1995031728A1 (en) * 1994-05-17 1995-11-23 Beki Ab Method of detecting cancer involving fragments of cytokeratin 18 and corresponding antibodies
US5932259A (en) * 1994-09-30 1999-08-03 Kato; Ken Bone reinforcing agent and foods and drinks product containing the same
WO2000011026A1 (en) * 1998-08-24 2000-03-02 Nst Neurosurvival Technologies Ltd. Basic peptides and pharmaceutical compositions containing same
US6296850B1 (en) * 1997-09-30 2001-10-02 Peviva Ab Apoptosis-related compounds and their use
US20020122791A1 (en) * 2000-12-21 2002-09-05 Nicolette Charles A. Antigenic CK-18 compounds for therapy and diagnosis and methods for using same
JP2002265495A (en) * 2001-03-09 2002-09-18 Taiho Yakuhin Kogyo Kk Basic new dendrimer or pharmaceutically acceptable salt thereof, and neovascularization inhibitor
US20030040475A1 (en) * 2001-01-16 2003-02-27 Yasuhiro Toba Agents for improving lipid metabolism and reducing high blood pressure
WO2003057168A2 (en) * 2002-01-03 2003-07-17 The Scripps Research Institute Cancer-associated epitope
US20030195144A1 (en) * 2000-03-09 2003-10-16 Svendsen John Sigurd Antimicrobial compounds and formulations

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3639580A (en) * 1970-01-08 1972-02-01 Akio Nagata Antibiotic tuberactinomycin and process for preparing same
US3880994A (en) * 1972-12-06 1975-04-29 Bristol Myers Co Antibiotic BU-1880
JPS511692A (en) * 1974-06-26 1976-01-08 Asahi Chemical Ind KOSEIBUTSUSHITSUKORISUCHINNO SEISEIHO
US4091092A (en) * 1976-09-20 1978-05-23 E. R. Squibb & Sons, Inc. Polymyxin F and process of producing polymyxin F
JPS63264599A (en) * 1987-04-20 1988-11-01 Takeda Chem Ind Ltd Antibiotic substance tan-865 and production thereof
JPH03206099A (en) * 1989-12-29 1991-09-09 Kaken Pharmaceut Co Ltd Antibiotic ksy-5 and production thereof
JPH0532557A (en) * 1991-02-27 1993-02-09 Morinaga Milk Ind Co Ltd Agent for promoting production of nerve growth factor
WO1993011783A1 (en) * 1991-12-09 1993-06-24 Magainin Pharmaceuticals Inc. Composition and treatment with biologically active peptides and chelating agents
WO1993024150A1 (en) * 1992-05-28 1993-12-09 Zeneca Limited Salts of peptides with carboxy-terminated polyesters
WO1995031728A1 (en) * 1994-05-17 1995-11-23 Beki Ab Method of detecting cancer involving fragments of cytokeratin 18 and corresponding antibodies
US5932259A (en) * 1994-09-30 1999-08-03 Kato; Ken Bone reinforcing agent and foods and drinks product containing the same
US6296850B1 (en) * 1997-09-30 2001-10-02 Peviva Ab Apoptosis-related compounds and their use
WO2000011026A1 (en) * 1998-08-24 2000-03-02 Nst Neurosurvival Technologies Ltd. Basic peptides and pharmaceutical compositions containing same
US20030195144A1 (en) * 2000-03-09 2003-10-16 Svendsen John Sigurd Antimicrobial compounds and formulations
US20020122791A1 (en) * 2000-12-21 2002-09-05 Nicolette Charles A. Antigenic CK-18 compounds for therapy and diagnosis and methods for using same
US20030040475A1 (en) * 2001-01-16 2003-02-27 Yasuhiro Toba Agents for improving lipid metabolism and reducing high blood pressure
JP2002265495A (en) * 2001-03-09 2002-09-18 Taiho Yakuhin Kogyo Kk Basic new dendrimer or pharmaceutically acceptable salt thereof, and neovascularization inhibitor
WO2003057168A2 (en) * 2002-01-03 2003-07-17 The Scripps Research Institute Cancer-associated epitope

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 197608, Derwent World Patents Index; Class B04, AN 1976-13936X, XP002307458 *
DATABASE WPI Section Ch Week 198849, Derwent World Patents Index; Class B04, AN 1988-351289, XP002307457 *
DATABASE WPI Section Ch Week 199142, Derwent World Patents Index; Class B04, AN 1991-307345, XP002307456 *
DATABASE WPI Section Ch Week 200343, Derwent World Patents Index; Class B04, AN 2003-451364, XP002307459 *
LEERS M P G ET AL: "IMMUNOCYTOCHEMICAL DETECTION AND MAPPING OF A CYTOKERATIN 18 NEO-EPITOPE EXPOSED DURING EARLY APOPTOSIS", JOURNAL OF PATHOLOGY, CHICHESTER, SUSSEX, GB, vol. 187, 1999, pages 567 - 572, XP001135112, ISSN: 0022-3417 *
PATENT ABSTRACTS OF JAPAN vol. 0173, no. 27 (C - 1073) 22 June 1993 (1993-06-22) *

Also Published As

Publication number Publication date
WO2005074968A2 (en) 2005-08-18

Similar Documents

Publication Publication Date Title
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
WO2005005599A3 (en) Modulation of c-reactive protein expression
WO2006124892A3 (en) Modulators of alpha-synuclein toxicity
ATE525372T1 (en) PYRAZINE DERIVATIVES AS SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN
WO2004093783A3 (en) Modulation of apolipoprotein c-iii expression
WO2004074434A3 (en) Methods and compositions for administering therapeutic and diagnostic agents
WO2004044181A3 (en) Antisense modulation of apolipoprotein b expression
NO20055209L (en) Peptabody for cancer treatment
ATE512663T1 (en) COMBINATION FOR THE TREATMENT OF CELL PROLIFERATION DISEASES
MXPA05010830A (en) Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin-2.
WO2007039728A3 (en) AVß6 PEPTIDE LIGANDS AND THEIR USES
GB0500231D0 (en) Compounds which bind to the active site of protein kinase enzymes
WO2003097662A8 (en) Antisense modulation of apolipoprotein b expression
WO2008064910A3 (en) Metastasis-specific peptides and their diagnostic and therapeutic applications
WO2004055162A3 (en) Modulation of endothelial lipase expression
WO2007062380A3 (en) Modulation of eif4e-bp2 expression
DE602005013650D1 (en) PROTEIN HYDROLYSATE FOR THE TREATMENT OF TIREDNESS
WO2006122971A3 (en) Treatment of disease using an improved regulated expression system
GB0500226D0 (en) Compounds which bind to the active site of protein kinase enzymes
WO2003076610A3 (en) Variants of human kallikrein-2 and kallikrein-3 and uses thereof
GB0328497D0 (en) Compounds which bind to the active site of protein kinase enzymes
WO2005074968A3 (en) Medical use of basic peptides
WO2003070169A3 (en) Aminodiphosphonate apolipoprotein e modulators
WO2003070878A3 (en) Antisense modulation of hematopoietic cell protein tyrosine kinase expression
WO2004089982A3 (en) April variants and methods thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase